Viela Bio, Inc.

( )
VIE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 0.46%74.100.0%$2395.49m
NVAXNovavax, Inc. 1.67%170.2999.2%$1218.87m
SRNESorrento Therapeutics, Inc. 5.95%14.421.8%$598.67m
GILDGilead Sciences, Inc. 0.79%69.351.0%$559.14m
AMGNAmgen, Inc. -0.36%240.691.3%$476.61m
REGNRegeneron Pharmaceuticals, Inc. -0.16%620.212.5%$429.51m
BNTXBioNTech SE -0.10%77.000.0%$399.56m
VRTXVertex Pharmaceuticals, Inc. -0.13%272.991.9%$368.45m
BIIBBiogen, Inc. 10.10%305.711.6%$361.06m
ILMNIllumina, Inc. -10.94%355.663.5%$336.82m
VXRTVaxart, Inc. 1.05%9.190.0%$280.99m
EBSEmergent BioSolutions, Inc. 2.91%130.666.4%$180.62m
ALXNAlexion Pharmaceuticals, Inc. -0.60%103.282.0%$166.60m
SGENSeattle Genetics, Inc. -0.83%160.456.0%$163.01m
IBIOiBio, Inc. -6.65%3.790.2%$158.51m

Company Profile

Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD.